DCM
TARA icon

DAFNA Capital Management’s Protara Therapeutics TARA Stock Holding History

DAFNA Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-318
Closed -$132K – 75
2014
Q4 		$132K Buy
+318
New +$128K 0.1% 59

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
DPA
Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

DAFNA Capital Management's TARA Position: Q1 2015 in Review

DAFNA Capital Management sold out of Protara Therapeutics (TARA) in Q1 2015, closing a stake of 318 shares — an estimated $132K sold.

DAFNA Capital Management first reported a position in TARA in Q4 2014 and held it in 1 quarter. The position peaked at $132K in Q4 2014. 22 funds tracked by Wall St. Rank hold TARA as of Q1 2015.

  • DAFNA Capital Management reported no remaining Protara Therapeutics position as of Q1 2015 after selling out during the quarter.
  • DAFNA Capital Management sold 318 Protara Therapeutics shares in Q1 2015, an estimated $132K.
  • DAFNA Capital Management first reported a position in Protara Therapeutics in Q4 2014 and held it in 1 quarter.
  • DAFNA Capital Management's Protara Therapeutics position peaked at $132K in Q4 2014.
  • 22 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2015.

Based on DAFNA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.